Your Catalyst To a Lucrative Business
The worldwide industry is segmented on the basis of technologies, applications, and regions. Based on
technologies, the categories are tumor cell detection & enrichment, centrifugation, molecular,
immunomagnetic, optical, filtration, and immunological. Tumor cell enrich ment & detection dominated the
market in 2013. High degree of accuracy, faster outcomes, and easy sample collection are factors that fuel
this segment. It may grow at a whopping CAGR of 27% from 2016 to 2024. Also, immunomagnetic &
immunological technologies may gain popularity during this period. This owes to their compatibility with all
genome sequencing and the capacity to facilitate effective analysis with smaller blood samples.
The areas of application are colorectal cancer, prostate cancer, and breas t cancer. The industry was led by
the breast cancer segment in 2013. Rising incidence of breast cancer attributes to high frequency of
malignancy and the growth of circulatory tumor cells from small sized primary tumors. What makes cancer a
terminal disease is the spreading of cancer cells to the healthier organs & body cells; a phenomenon known
as metastasis.
Geographically, the industry is categorized into North America, Europe, Asia Pacific, and Rest of the World.
North America is a strong regional market that is driven by favorable government initiatives, exhaustive R&D
activities, and updated technology infrastructure. Growing patient awareness too plays a vital role in
positively influencing this regional market. It is expected that Asia Pacific econo mies, such as China and India
will witness considerable growth during the forecast period. The region is propelled by growing awareness
about hospital acquired infections and surging healthcare expenditure.
Prominent companies operating in the worldwide Circulating Tumor Cells Market are AVIVA BioSciences
Corporation; Advanced Cell Diagnostics Inc.; Silicon Biosystems, Vitatex Inc.; and Veridex LLC. Clinicians &
researchers for a long time have tried developing effective methods for cancer screening & its progression.
Commonly used methods involve blood tests for screening biomarkers. For example, PSA (prostate -specific
antigen) levels are indicators of prostate cancer. Other frequently employed screening methods are MRI
(magnetic resonance imaging) or computed tomography. However, one particular approach that holds good
promise is the analysis of CTCs (circulating tumor cells). Scientists point out that the genetic analysis of CTCs
could throw light on patients’ suitability for targeted cancer therapies. Th is could help determine the
mutational landscape of tumors as well.
Browse Related Category Market Reports @ https://www.hexaresearch.com/research-category/biotechnology-
industry
Follow Us: